Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Menlo Therapeutics Inc (MNLO)

Menlo Therapeutics Inc (MNLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 226,383
  • Shares Outstanding, K 167,691
  • Annual Sales, $ 0 K
  • Annual Income, $ -73,700 K
  • 60-Month Beta 1.07
  • Price/Sales 16.84
  • Price/Cash Flow N/A
  • Price/Book 3.16
Trade MNLO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.75
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 10/29/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.18
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.19
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +74.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 +3.85%
on 09/04/20
1.8500 -27.03%
on 08/05/20
-0.4200 (-23.73%)
since 08/04/20
3-Month
1.3000 +3.85%
on 09/04/20
2.3700 -43.04%
on 06/19/20
-0.8600 (-38.91%)
since 06/04/20
52-Week
1.0000 +35.00%
on 04/08/20
7.4800 -81.95%
on 01/17/20
-3.4700 (-71.99%)
since 09/04/19

Most Recent Stories

More News
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team

Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical...

ASND : 142.87 (-1.35%)
KALV : 10.76 (-4.01%)
ACRS : 1.2150 (-0.41%)
BHVN : 39.35 (-0.66%)
MNLO : 1.3500 (-2.17%)
SRRA : 54.99 (+0.04%)
BIOD : 0.65 (+6.56%)
VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September

BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present...

MNLO : 1.3500 (-2.17%)
VYNE : 2.37 (+2.16%)
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics

Will commence trading under new Nasdaq Ticker “VYNE”, September 8, 2020

MNLO : 1.3500 (-2.17%)
VYNE : 2.37 (+2.16%)
Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics

Company will commence trading under new ticker “VYNE” on September 8, 2020

MNLO : 1.3500 (-2.17%)
Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update

Conference Call Today at 8:30am Eastern Time

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6

BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Announces Pricing of Offering of Common Stock

BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies...

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Announces Proposed Offering of Common Stock

BRIDGEWATER, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies...

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris

The Company plans to present trial data along with a proposed Phase 3 development program in an End of Phase 2 meeting with the FDA before the end of this year

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea

ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults

MNLO : 1.3500 (-2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 1.4367
1st Resistance Point 1.3933
Last Price 1.3500
1st Support Level 1.3033
2nd Support Level 1.2567
3rd Support Level N/A

See More

52-Week High 7.4800
Fibonacci 61.8% 5.0046
Fibonacci 50% 4.2400
Fibonacci 38.2% 3.4754
Last Price 1.3500
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar